ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model

J. Kwun1, R. Schmitz1, M. Manook1, Z. Fitch1, D. Olaso1, A. Choi1, J. Yoon1, Y. Bae1, J. Lambris2, S. Knechtle1

1Surgery, Duke University, Durham, NC, 2Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

Meeting: 2021 American Transplant Congress

Abstract number: 345

Keywords: Alloantibodies, B cells, Immunosuppression, Kidney transplantation

Topic: Basic Science » Immunosuppression Preclinical Studies

Session Information

Session Name: Xenotranplantation and Preclinical Studies

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 8, 2021

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:15pm-6:20pm

Location: Virtual

*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience antibody-mediated rejection (AMR) with limited effective treatment options. We tested a novel treatment strategy for AMR consisting of complement inhibition, proteasome inhibition and costimulation blockade in a nonhuman primate model.

*Methods: Thirteen rhesus macaques were sensitized to maximally MHC mismatched donors by two sequential skin transplants. Primates subsequently received kidney allografts from their skin donors. All primates received induction therapy with rhesus-specific ATG (rhATG) and were maintained on different immunosuppressive regimens. Primates were monitored postoperatively for signs of AMR, which was defined as worsening kidney function resistant to high dose steroid rescue therapy, a rise in serum donor-specific antibody (DSA) levels, and biopsy evidence of active AMR. AMR treatment consisted of carfilzomib and belatacept for a maximum of 4 weeks.

*Results: Treatment with carfilzomib and belatacept was well tolerated and we did not observe any treatment-specific side effects. Once AMR developed, animals without further treatment rejected their graft rapidly. However, animals treated with carfilzomib and belatacept showed prolonged graft survival after the AMR treatment compared to control animals (5d vs. 28.5d, p < 0.01; Figure 1A). As shown in figure 1B, animals without treatment showed significant elevation of serum creatinine (sCr) while profound reduction of sCr was observed in treated animals. After initiation of treatment, we observed a significant reduction of both class I and class II DSA (Figure 1C). However, all animals showed rebound of DSA when the treatment was discontinued.

*Conclusions: Carfilzomib and belatacept were able to control on-going humoral immune response seen during AMR in a nonhuman primate model. This was associated with improved graft function and prolongation of graft survival. Further studies in optimizing maintenance immunosuppression after carfilzomib and belatacept treatment is warranted to continuously control post-transplant humoral response in the sensitized recipients.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kwun J, Schmitz R, Manook M, Fitch Z, Olaso D, Choi A, Yoon J, Bae Y, Lambris J, Knechtle S. Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/belatacept-and-carfilzomib-based-treatment-of-active-antibody-mediated-rejection-in-a-sensitized-nonhuman-primate-model/. Accessed May 9, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences